ScemblixActive Ingredient(s): Asciminib Hydrochloride
FDA Approved: * October 29, 2021
Pharm Company: * NOVARTIS
Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Asciminib is a protein kinase inhibitor. The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea. Asciminib was approved for medical use in the United States in October 2021.&a... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.